Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
SCHAUMBURG, Ill., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 13, 2016 at 2:00 p.m. PT (4:00 p.m. CT/5:00 p.m. ET). The presentation is being webcast and can be accessed on the "Events and Presentations" page of the "Investor Relations" section of the Company's website, www.sagentpharma.com. In order to register and download any necessary software, please log on 10 minutes prior to the start of the webcast.
A replay of the webcast will be available until Tuesday, February 16, 2016 and can be accessed on the Sagent website.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., founded in 2006, is a global specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.
INVESTOR CONTACT: Jonathon Singer, Sagent [email protected] 847-908-1605
